Please login to the form below

Not currently logged in

Immodulon Therapeutics appointments two new board of directors

Anthony Bolton and Sir Simon Robertson join the biopharma firm

Sir Simon RobertsonImmodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology has made two new senior appointments to its board of directors.

Anthony Bolton, one of the UK's most successful investment fund managers and Sir Simon Robertson (pictured), deputy chairman of HSBC, will join Immodulon as non-executive directors with immediate effect.

Bolton joined Fidelity in 1979. He has managed several Fidelity funds including the Fidelity Special Situations that he ran for 28 years up to 2007. During this time the fund became the largest unit trust in the UK and achieved annual growth of almost 20%. 

More recently, he wrote an investment book 'Investing Against the Tide' and managed Fidelity China Special Situations PLC whilst based in Hong Kong for four years.

Although he retired from fund management in 2014 he remains a board member and adviser at Fidelity as well as a trustee of its charitable foundations.

Sir Simon joined the board of HSBC in 2006 and has served on a number of board committees. 

He has an extensive background in international corporate advisory work and a wealth of experience in mergers and acquisitions and financial markets. 

His international experience includes working in France, Germany, the UK and the US. He was knighted in the 2010 Queen's birthday honours list in recognition of his services to business.

16th June 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...